Where MDMA Therapy Is Legal in 2026 — and What Access Actually Costs

"Is MDMA therapy legal?" has a different answer depending on which country you are standing in, which diagnosis you carry, and which clinician you can reach. Here is the map as it stands.

Australia: legal, narrow, and tightening

Australia is the only country where a patient can be prescribed MDMA for PTSD through a legal clinical route. Following the 2023 decision to down-schedule MDMA to Schedule 8 for post-traumatic stress disorder, a psychiatrist who is an Authorised Prescriber under the Therapeutic Goods Administration may prescribe it — but only for PTSD, and only with permission from a human research ethics committee. For any other use, MDMA remains Schedule 9, a prohibited substance. Psilocybine is listed the same way, for treatment-resistant depression.

The route is deliberately restrictive. The TGA's own consumer guidance states plainly that MDMA and psilocybine are unapproved medicines — they have not been evaluated by the TGA for quality, safety and efficacy and are not on the Australian Register of Therapeutic Goods. General practitioners and medical specialists who are not Authorised Prescribers cannot legally deliver the treatment, and the Department of Veterans' Affairs repeats that limit for veterans seeking psychedelic-assisted psychotherapy.

In mid-2026 the TGA moved to tighten it further, announcing review recommendations focused on psychiatrist competency requirements, therapy team composition, prescriber oversight and treatment site standards. Freedom-of-information data released in September 2026, current to 31 July 2026, shows the number of prescribers approved since rescheduling — a small group relative to the number of Australians with PTSD.

United States: not approved, and the application is contested

There is no legal prescription route in the US. On 8 August 2024 the FDA issued a complete response letter rejecting Lykos Therapeutics' application for MDMA-assisted therapy for PTSD, asking for a new randomised, double-blind Phase 3 trial and an independent audit of study records. In August 2026 it was reported that Resilient Pharmaceuticals had resubmitted the application to the FDA without conducting the new Phase 3 trial the agency had requested — a move that, if accurate, sets up the same disagreement over whether the existing evidence is sufficient.

Until that is resolved, any US clinic offering MDMA-assisted therapy is operating outside an approved pathway, whatever it calls itself.

Canada and much of Europe: case-by-case at best

Outside Australia, access generally runs through special-access or named-patient schemes, health-authority exemptions, or research protocols. These are individual permissions granted for an individual patient, not a service you can enrol in, and they are usually granted to people who have already failed conventional treatment.

What access actually costs

Even where the treatment is lawful, the practical barriers are financial and logistical:

• The treatment is not a single appointment. A course runs over roughly three months with preparation sessions, one to three dosing sessions, and integration sessions. The clinician's hours, not the dose, are the cost driver.
• Public funding is largely absent. In Australia, the authorised-prescriber route does not come with a public subsidy for the therapy hours, and the Department of Veterans' Affairs covers the treatment only within its own specified arrangements.
• Travel is usually required. Authorised Prescribers are concentrated in capital cities and a handful of private clinics, so many patients pay for accommodation across a three-month course.
• Time off work is not optional. Dosing days end in the evening and the following day is kept clear, repeated for each session.

The honest summary

For most readers, MDMA-assisted therapy is not currently an option they can simply choose. That is not only a regulatory failure — it reflects a genuine unresolved argument about how well the treatment has been demonstrated. The research reporting on this site is written for people who want to follow that argument, not for people who want a referral.

If you are in Australia with PTSD, the practical first step is the TGA's consumer page and a psychiatrist who is an Authorised Prescriber. If you are elsewhere, the realistic first step is a clinical trial, and our Trials section lists what is recruiting.